India, Sept. 11 -- Biocon announced the inauguration of its first U.S. manufacturing facility in Cranbury, New Jersey, by its wholly owned subsidiary, Biocon Generics Inc (BGI).Biocon acquired the Oral Solid Dosage (OSD) facility from Eywa Pharma Inc. in 2023 and has since invested over USD 30 million to establish a state-of-the-art plant with an annual production capacity of 2 billion tablets. A few products have already been commercialized from the site, with several more in the pipeline. This investment helps Biocon diversify its manufacturing base, strengthen its supply chain and accelerate the expansion of its global footprint.The Cranbury facility represents a strategic advancement for the Company's U.S. operations, enabling faster ac...